Viracta Therapeutics, Inc. (VIRX)
OTCMKTS · Delayed Price · Currency is USD
0.0098
+0.0002 (1.88%)
Inactive · Last trade price on Jul 16, 2025
Viracta Therapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
40
Market Cap
n/a
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionViracta Therapeutics News
- 7 months ago - Viracta Therapeutics Announces Wind Down of Operations - GlobeNewsWire
- 8 months ago - Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives - GlobeNewsWire
- 10 months ago - Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 1 year ago - Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 1 year ago - Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan - GlobeNewsWire
- 1 year ago - Viracta Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 1 year ago - Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer - GlobeNewsWire
- 1 year ago - Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire